Investors in AngioDynamics (NASDAQ:ANGO) have unfortunately lost 75% over the last three years [Yahoo! Finance]
AngioDynamics, Inc. (ANGO)
Last angiodynamics, inc. earnings: 4/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.angiodynamics.com/investor-relations
Company Research
Source: Yahoo! Finance
So spare a thought for the long term shareholders of AngioDynamics, Inc. NASDAQ:ANGO ); the share price is down a whopping 75% in the last three years. That would be a disturbing experience. And the ride hasn't got any smoother in recent times over the last year, with the price 39% lower in that time. On top of that, the share price is down 7.9% in the last week. With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies. See our latest analysis for AngioDynamics Given that AngioDynamics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally hope to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. In the last three years, AngioDynamics saw its revenue grow by 5.8% per year, compound. Tha
Show less
Read more
Impact Snapshot
Event Time:
ANGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANGO alerts
High impacting AngioDynamics, Inc. news events
Weekly update
A roundup of the hottest topics
ANGO
News
- Venous Thromboembolism Treatment Market to be Worth $4.40 Billion by 2030 - Exclusive Report by Meticulous Research® [Yahoo! Finance]Yahoo! Finance
- First patient implanted with Philips' Duo Venous stent system [Yahoo! Finance]Yahoo! Finance
- AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval [Yahoo! Finance]Yahoo! Finance
- AngioDynamics, Inc. (NASDAQ: ANGO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.MarketBeat
- AngioDynamics receives CE Mark approval in Europe for AlphaVac F1885 System [Seeking Alpha]Seeking Alpha
ANGO
Earnings
- 4/4/24 - Miss
ANGO
Sec Filings
- 5/30/24 - Form SC
- 4/9/24 - Form 10-Q
- 4/8/24 - Form 4
- ANGO's page on the SEC website